Intas – Oncology Medicines & Biosimilars
Intas
Intas Pharmaceuticals Ltd. is an Indian pharmaceutical company headquartered in Ahmedabad, Gujarat. It was founded in the 1970s by pharmacist Hasmukh Chudgar. The company is privately held: the Chudgar family owns the majority, with minority stakes held by the investment firms Temasek and ChrysCapital.
Intas makes generic medicines for chronic and serious conditions, with oncology and injectable products playing a major role. It was one of the first Indian companies in biosimilars: its biotech facility received EU GMP certification in 2007, and in 2015 Intas launched a filgrastim biosimilar in Europe. The company also runs a plasma fractionation centre and a cell and gene therapy centre.
Outside India, Intas operates through its London-based subsidiary Accord Healthcare, which sells generics in Europe and North America. In 2017 Intas acquired Actavis's UK and Irish business from Teva. According to the company, about 70% of its revenue comes from international markets, mainly the EU and the US, and its medicines are available in more than 85 countries.
Unifarm carries Intas medicines: Tofatas (tofacitinib, 2% ointment), Glycolate 1 and Glycolate 2 (glycopyrrolate), and Vasfree 100 (flupirtine).